First DataBank's FIRSTLight Goes Live

First DataBankFirst DataBank's new online medicines reference tool, FIRSTLight, is now live and First DataBank is offering a free extended trial until the end of January 2011. FIRSTLight provides instant access to reliable medicines information, empowering clinicians and supporting safer, faster clinical decision making.

This is the first time First DataBank's trusted medicines information has been available stand alone and accessible at any point in the clinical workflow.

"We introduce FIRSTLight in direct response to requests from individual clinicians and Trusts for instant access to First DataBank's complete electronic medicines information," says Polly Shepperdson, Product Manager at First DataBank.

Several clinical system vendors have expressed early interest in partnering opportunities. Darren Nichols, Managing Director of First DataBank, comments: "Our current business partners are keen to add the immediate value and benefit of FIRSTLight to support their customers' medicines managements needs."

Specific features of FIRSTLight include:

  • How, when and when not to use a medication including ingredients, indications, doses, routes and administration advice
  • When to avoid using a medication, information about allergies and safety of use with other concurrent conditions, drugs and food
  • Tests, measures and observations required while using a medication including what should be done about any resulting changes, along with information about managing expected side effects and what to do in cases of over-dosage
  • Reproduction, pregnancy and breastfeeding advice including whether taking the medication can affect fertility, relevant recommendations for use of contraception and any risks associated with pregancy or breastfeeding while taking the medication.

FIRSTLight iPhone and iPad applications will also be available in early 2011.

To begin using FIRSTLight today, sign up for your free trial at www.firstdatabank.co.uk/firstlight

Related news articles:

About First DataBank
First DataBank is the UK's leading provider of drug knowledge bases and active clinical decision support. With over 30 years' experience of maintaining, developing and integrating drug knowledge bases across the entire healthcare spectrum, First DataBank has unrivalled expertise and knowledge in this specialist field. NHS Connecting for Health has chosen First DataBank to provide drug-related clinical decision support.

Patient safety is the driving force behind our business. Through the effective integration of our products into clinical systems, we enable safer prescribing, dispensing and administration.

Our Multilex Drug Data File - the UK's most comprehensive and widely used drug knowledge base - is in daily use by thousands of healthcare professionals in the UK.

For further information visit www.firstdatabank.co.uk.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...